Publications by authors named "John D Abad"
Background And Objectives: The PROSPECT trial showed noninferiority of neoadjuvant chemotherapy (NAC) with selective chemoradiation (CRT) versus CRT alone. However, trial results are often difficult to reproduce with real-world data. Pathologic outcomes and overall survival (OS) were evaluated by neoadjuvant strategy in locally advanced rectal adenocarcinoma patients in a national database.
View Article and Find Full Text PDFArticle Synopsis
- Neoadjuvant chemotherapy (NAC) and chemoradiation (NCRT) are treatments for locoregional gastric cancer, but their effectiveness in improving survival is still debated.
- In a study analyzing data from 9,831 patients, NCRT led to better histopathologic outcomes like pathologic complete response and margin-negative resections, while NAC showed improved overall survival rates.
- Further research is necessary to understand how histologic assessments after neoadjuvant therapy can impact prognostication for patients with gastric cancer.
Introduction: Accurate clinical staging (CS) of gastric adenocarcinoma is important to guide treatment planning. Our objectives were to (1) assess clinical to pathologic stage migration patterns for patients with gastric adenocarcinoma, (2) identify factors associated with inaccurate CS, and (3) evaluate the association of understaging with survival.
Methods: The National Cancer Database was queried for patients who underwent upfront resection for stage I-III gastric adenocarcinoma.
Adoptive cell transfer therapy using tumor-infiltrating lymphocytes for patients with metastatic melanoma has demonstrated significant objective response rates. One major limitation of these current therapies is the frequent inability to isolate tumor-reactive lymphocytes for treatment. Genetic engineering of peripheral blood lymphocytes with retroviral vectors encoding tumor antigen-specific T-cell receptors (TCRs) bypasses this restriction.
View Article and Find Full Text PDF